332 related articles for article (PubMed ID: 18693169)
1. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.
Lu AW; Zheng SS; Wu MP; Shen Y; Yang RW
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):357-61. PubMed ID: 18693169
[TBL] [Abstract][Full Text] [Related]
2. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
4. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
[TBL] [Abstract][Full Text] [Related]
5. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
6. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
[TBL] [Abstract][Full Text] [Related]
7. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
8. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
[TBL] [Abstract][Full Text] [Related]
11. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
12. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
13. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
Gao YJ; Zhang M; Jin B; Meng FP; Ma XM; Liu ZW; Su HB; Zhao JM; Li HW
J Gastroenterol Hepatol; 2014 Mar; 29(3):554-60. PubMed ID: 24117714
[TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
Buti M; Mas A; Prieto M; Casafont F; González A; Miras M; Herrero JI; Jardí R; Cruz de Castro E; García-Rey C
J Hepatol; 2003 Jun; 38(6):811-7. PubMed ID: 12763375
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
[TBL] [Abstract][Full Text] [Related]
18. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
[TBL] [Abstract][Full Text] [Related]
20. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]